Biocept, Inc. (NASDAQ: BIOC)
Biocept has had a pretty tough time in the market over the past week. However, I recently published an article explaining why the lows were presenting an opportunity with this one. Today, BIOC is making good on that prediction with big gains. Here’s why it’s happening, what we’re seeing, and what we can expect to see moving forward.
Breast Cancer Biopsy
Brest cancer is a major issue in the US and around the world. One of the biggest problems is that women simply aren’t getting checked as often as they should. However, could you imagine a world where a mammogram followed by a tissue biopsy wasn’t needed to diagnose the condition? Biocept can!
As a matter of fact, Biocept recently released data of a study that aimed to do just that. Their data showed that when a standard blood sample is tested using their methods, they produce the same results as a tissue biopsy. While this has only been tested in specific forms of breast cancer, one could only imagine how expansion of this technology could not only be profitable, but save lives! Think about it, years from now, cancer testing could become part of standard blood testing we go through all the time…increasing awareness of early stage cancer and survival rates along with it. The bottom line is that this technology is absolutely amazing.
What We’re Seeing From BIOC Today
While early morning blues brought Biocept down in early morning trading, the stock reached support around 10:00 and started to see pretty decent climbs around 11:00. Since then, it’s been on the up and up. Currently (12:35), Biocept is trading at $2.93 per share after a gain of 7.57% so far today.
What We Can Expect To See From Biocept Moving Forward
If you can’t tell from what I said about the company above, I’ve got incredibly high hopes for this one. Sure, the technology is still in the testing phase, and is only being tested on very select types of cancer. However, the results we’ve seen show proof of concept in an amazing new technology that will most likely only get better from here. With that said, I’m expecting to see long term gains from BIOC.
What Do You Think?
Where do you think BIOC is headed and why? Let us know in the comments below!